| 胃肠道间质瘤的诊治新进展 |
| |
| 引用本文： | 金晓辉,丁小云. 胃肠道间质瘤的诊治新进展[J]. 国外医学:内科学分册, 2009, 36(5): 282-285 |
| |
| 作者姓名： | 金晓辉 丁小云 |
| |
| 作者单位： | 宁波大学医学院附属宁波市第一医院消化内科,浙江,宁波,315010;宁波大学医学院附属宁波市第一医院消化内科,浙江,宁波,315010 |
| |
| 摘 要： | 胃肠道间质瘤（GIST）是胃肠道最常见的间叶源性肿瘤,原癌基因c—kit突变是其主要发病机制之一。以CD117为代表的免疫织化学染色在其诊断中是一个重要的决定性因素。手术完整切除仍然是其首选治疗,分子靶向治疗是进展期GIST治疗上的一次飞跃,本文对GIST的诊治新进展进行综述。
|
| 关 键 词： | 胃肠道间质瘤 C-kit CD117 伊马替尼 分子靶向治疗 |
Development in diagnosis and therapy of gastrointestinal stromal tumor |
| |
| JIN Xiao-hui,DING Xiao-yun. Development in diagnosis and therapy of gastrointestinal stromal tumor[J]. Foreign Medical Sciences(Section of Internal Medicine), 2009, 36(5): 282-285 |
| |
| Authors: | JIN Xiao-hui DING Xiao-yun |
| |
| Affiliation: | JIN Xiao-hui, DING Xiao-yun. (Department of Gastroenterology, Ningbo First Hospital, Medical College of Ningbo University, Ningbo 315010, China) |
| |
| Abstract: | Gastrointestinal stromal tumors （GISTs） are the most common mesenchymal tumors of the gastrointestinal tract. They are characterized by oncogenic mutations of the KIT receptor tyrosine kinase in a majority of patients. KIT is used not only for diagnosis but also for targeted therapy of GISTs. Imatinib is widely used in the treatment of advanced and metastatic GISTs and has been recently employed in the neoadjuvant and adjuvant set-up. New therapeutic agents like Sunitinib have now been approved for the treatment of Imatinib-resistant GISTs. This review summarizes the development in diagnosis and therapy of GISTs. |
| |
| Keywords: | C-kit CD117 |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
